SE0002189D0 - New method and assay - Google Patents

New method and assay

Info

Publication number
SE0002189D0
SE0002189D0 SE0002189A SE0002189A SE0002189D0 SE 0002189 D0 SE0002189 D0 SE 0002189D0 SE 0002189 A SE0002189 A SE 0002189A SE 0002189 A SE0002189 A SE 0002189A SE 0002189 D0 SE0002189 D0 SE 0002189D0
Authority
SE
Sweden
Prior art keywords
irs
assay
sequences
diabetes
markers
Prior art date
Application number
SE0002189A
Other languages
English (en)
Inventor
Ulf Smith
Original Assignee
Metcon Medicin Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metcon Medicin Ab filed Critical Metcon Medicin Ab
Priority to SE0002189A priority Critical patent/SE0002189D0/sv
Publication of SE0002189D0 publication Critical patent/SE0002189D0/sv
Priority to EP01941363A priority patent/EP1287030A1/en
Priority to US09/875,945 priority patent/US6835819B2/en
Priority to PCT/SE2001/001308 priority patent/WO2001094410A1/en
Priority to AU2001274722A priority patent/AU2001274722A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
SE0002189A 2000-06-08 2000-06-09 New method and assay SE0002189D0 (sv)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE0002189A SE0002189D0 (sv) 2000-06-09 2000-06-09 New method and assay
EP01941363A EP1287030A1 (en) 2000-06-08 2001-06-08 Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof
US09/875,945 US6835819B2 (en) 2000-06-08 2001-06-08 Sequences and their use
PCT/SE2001/001308 WO2001094410A1 (en) 2000-06-08 2001-06-08 Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof
AU2001274722A AU2001274722A1 (en) 2000-06-08 2001-06-08 Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002189A SE0002189D0 (sv) 2000-06-09 2000-06-09 New method and assay

Publications (1)

Publication Number Publication Date
SE0002189D0 true SE0002189D0 (sv) 2000-06-09

Family

ID=20280058

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002189A SE0002189D0 (sv) 2000-06-08 2000-06-09 New method and assay

Country Status (2)

Country Link
US (1) US6835819B2 (sv)
SE (1) SE0002189D0 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060316A2 (en) * 2003-01-02 2004-07-22 Housey Gerard M Irs modulators
KR20180056816A (ko) * 2009-05-11 2018-05-29 베르그 엘엘씨 환경대사적 전환인자（조효소 ｑ１０）를 사용한 질환의 치료 방법
WO2010135695A2 (en) * 2009-05-22 2010-11-25 Curna, Inc. TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
SG10201907816RA (en) 2013-09-04 2019-09-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578444A (en) 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5858701A (en) 1994-10-03 1999-01-12 Joslin Diabetes Center, Inc. DNA encoding an insulin receptor substrate
AU7181198A (en) 1996-11-13 1998-06-03 Receptron Corporation Assays for non-insulin dependent diabetes
CA2293363A1 (en) 1997-06-11 1998-12-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them

Also Published As

Publication number Publication date
US20020098169A1 (en) 2002-07-25
US6835819B2 (en) 2004-12-28

Similar Documents

Publication Publication Date Title
Gross et al. Therapeutic strategies in fragile X syndrome: from bench to bedside and back
Haeberle et al. Molecular profiling reveals synaptic release machinery in Merkel cells
Schultze Reprogramming of macrophages—new opportunities for therapeutic targeting
Schedle et al. Response of L-929 fibroblasts, human gingival fibroblasts, and human tissue mast cells to various metal cations
Kis et al. Putative cyclooxygenase-3 expression in rat brain cells
Kitami et al. A chemical screen probing the relationship between mitochondrial content and cell size
Tanaka et al. Cyclic mechanical strain regulates the PTHrP expression in cultured chondrocytes via activation of the Ca2+ channel
Zhang et al. Cerebral mast cells participate in postoperative cognitive dysfunction by promoting astrocyte activation
DK1666052T3 (da) Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
Hyrien et al. Mathematical and experimental approaches to identify and predict the effects of chemotherapy on neuroglial precursors
Bohannon et al. Optogenetic dissection of roles of specific cortical interneuron subtypes in GABAergic network synchronization
Tossidou et al. SUMOylation determines turnover and localization of nephrin at the plasma membrane
ATE527378T1 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
Shi et al. Induction of matrix metalloproteinase-3 (MMP-3) expression in the microglia by lipopolysaccharide (LPS) via upregulation of glycoprotein nonmetastatic melanoma B (GPNMB) expression
Parfitt et al. Transcriptome analysis of aging mouse meibomian glands
Benatti et al. Influence of aging on biological properties of periodontal ligament cells
BRPI0406680A (pt) Métodos para selecionar um animal para ter propriedades desejadas genotìpicas ou fenotìpicas em potencial, para modular a trascrição de mrna de um gene igf2 em uma célula ou organismo provido com referido gene e para identificar um composto, composto, composição farmacêutica, e, uso de um composto
Ruiz-Romero et al. Hypoxia conditions differentially modulate human normal and osteoarthritic chondrocyte proteomes
Nakao et al. Proteoglycan expression is influenced by mechanical load in TMJ discs
SE0002189D0 (sv) New method and assay
Walker et al. Cerebral and skeletal muscle feed artery vasoconstrictor responses in a mouse model with greater large elastic artery stiffness
Yang et al. Interferonregulatoryfactor-8 (IRF-8) regulates the expression of matrix metalloproteinase-13 (MMP-13) in chondrocytes
WO2006091964A3 (en) Regulators of protein misfolding and aggregation and methods of using the same
Haws et al. Cutaneous findings in Bardet‐Biedl syndrome
Horvath et al. Methylation studies in Peromyscus: aging, altitude adaptation, and monogamy